<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908553</url>
  </required_header>
  <id_info>
    <org_study_id>2021S027</org_study_id>
    <nct_id>NCT04908553</nct_id>
  </id_info>
  <brief_title>Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults</brief_title>
  <official_title>Safety and Dose Exploration of Remimazolam Tosilate for Injection for Induction and Maintenance of General Anesthesia Intubation for Elective Short-term Surgery in Adults: a Multi-center, Randomized, Double-blind Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research objective: To explore the safety and dose exploration of Remimazolam Tosilate for&#xD;
      Injection for induction and maintenance of general anesthesia in elective short-term surgery&#xD;
      in adults.&#xD;
&#xD;
      Main research indicators:(1)Success rate of sedation during induction and maintenance of&#xD;
      general anesthesia with remazolam tosylate;(2)The incidence and severity of hypotension in&#xD;
      the induction and maintenance phases Study design: Multi-center, randomized, double-blind&#xD;
      clinical study. Subject population: patients undergoing elective short-term surgery. Research&#xD;
      data collection period: The subject signs the consent form until discharge or death in the&#xD;
      hospital or withdrawal from the research.&#xD;
&#xD;
      Number of research centers/sample size: It is planned to enroll 600 patients from 11&#xD;
      hospitals.&#xD;
&#xD;
      Research process: The researchers will include patients who meet the enrollment criteria and&#xD;
      agree to participate in the investigation of the support laryngoscope surgery and minor head&#xD;
      and neck surgery patients from the elective surgery patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data collected in this study is recorded by the researcher in the eCRF, including:&#xD;
&#xD;
        1. Data to be collected during the screening period and before the operation: the basic&#xD;
           characteristics of the patient and demographic data;&#xD;
&#xD;
        2. Data to be recorded during and/or postoperatively: main research indicators, secondary&#xD;
           indicators and other indicators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hypotension during the anesthesia</measure>
    <time_frame>during the anesthesia procedure</time_frame>
    <description>The systolic blood pressure during the anesthesia is ≤ 90 mmHg, or a reduction of &gt;20% from the baseline period, or the average blood pressure is &lt;65 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of Successful sedation during the anesthesia</measure>
    <time_frame>during the anesthesia procedure</time_frame>
    <description>Successful sedation during the anesthesia is defined as: 1) successful induction of anesthesia without anesthesia remedial measures during the induction period; 2) no recovery during the anesthesia maintenance period, no unexpected physical activity, and no remedial measures during the maintenance period anesthesia.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hypotension During Surgery</condition>
  <arm_group>
    <arm_group_label>low dose group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Remimazolam Tosilate for Injection 0.1mg/kg at induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Remimazolam Tosilate for Injection 0.15mg/kg at induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Remimazolam Tosilate for Injection 0.2mg/kg at induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate for Injection 0.1mg/kg</intervention_name>
    <description>Remimazolam Tosilate for Injection 0.1mg/kg at induction</description>
    <arm_group_label>low dose group</arm_group_label>
    <other_name>low dose group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate for Injection 0.15mg/kg</intervention_name>
    <description>Remimazolam Tosilate for Injection 0.15mg/kg at induction</description>
    <arm_group_label>medium dose group</arm_group_label>
    <other_name>medium dose group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate for Injection 0.2mg/kg</intervention_name>
    <description>Remimazolam Tosilate for Injection 0.2mg/kg at induction</description>
    <arm_group_label>high dose group</arm_group_label>
    <other_name>high dose group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ASA Ⅰ-Ⅲ grade;&#xD;
&#xD;
          2. age 18-65 years old;&#xD;
&#xD;
          3. gender is not limited;&#xD;
&#xD;
          4. planned elective support laryngoscope surgery (glottic polypectomy under support&#xD;
             laryngoscope, epiglottic cyst excision under support laryngoscope, benign laryngeal&#xD;
             under support laryngoscope Lesion resection), endoscopic septoplasty, endoscopic&#xD;
             tympanoplasty, endoscopic middle ear tube insertion, nasopharyngoplasty, head and neck&#xD;
             benign mass resection for general anesthesia intubation patients;&#xD;
&#xD;
          5. operation time No more than 90min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Emergency surgery;&#xD;
&#xD;
          1. abnormal renal function (urea nitrogen ≥1.5×ULN, blood creatinine greater than the&#xD;
             upper limit of normal);&#xD;
&#xD;
          2. abnormal liver function;&#xD;
&#xD;
          3. hypovolemia, shock or coma;&#xD;
&#xD;
          4. suffering from mental illness and long-term use of psychotropic drugs;&#xD;
&#xD;
          5. cognition Dysfunction;&#xD;
&#xD;
          6. those who are allergic to or contraindicated to benzodiazepines and their drug&#xD;
             components; pregnant or lactating female patients;&#xD;
&#xD;
          7. have a history of drug dependence;&#xD;
&#xD;
          8. have used other sedatives in the past week;&#xD;
&#xD;
          9. have been a subject within the past 3 months Participated in drug clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ailin Luo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ailin Luo, Doctor</last_name>
    <phone>13507122565</phone>
    <email>alluo@hust.edu.cn</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Ailin Luo</investigator_full_name>
    <investigator_title>Principal Investigator, professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

